{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003420","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.137569+00:00","generated_at":"2026-06-07T01:46:17.817480+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%","bullets":["Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).","Julie Andrews named CFO, effective Jan 15; base salary $475K, target bonus 70%, sign-on equity $1.8M.","Kevin Kenny departed as officer Jan 8; eligible for severance and $500/hr consulting for 12 months.","Q4 preliminary net sales $200.3M, +63.8% reported (+7.5% pro forma); BGT up 15.3%.","Full-year 2023 net sales $746.5M, +62% reported (+6.5% pro forma)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003420","json":"https://secwatch.observer/filing/0000950170-24-003420.json","markdown":"https://secwatch.observer/filing/0000950170-24-003420.md","text":"https://secwatch.observer/filing/0000950170-24-003420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/ofix-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:46:17.817480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3f61ca6d7be150e4846f9264fc3a4be4978e536","claim":"Orthofix Medical Inc. reported the fiscal quarter and year ended December 31, 2023 results: revenue $200.3 million.","evidence_excerpt":"Net sales of $200.3 million, an increase of 64% on a reported basis and an increase of 8% on a pro forma basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$200.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"19fd165afe","claim":"Julie Andrews was appointed as Chief Financial Officer at Orthofix Medical Inc..","evidence_excerpt":"the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6705462a45","claim":"Massimo Calafiore was appointed as President and Chief Executive Officer at Orthofix Medical Inc..","evidence_excerpt":"the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}